218. Alport syndrome Clinical trials / Disease details

Clinical trials : 26 / Drugs : 33 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 29

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004394-10-DE (EUCTR)	30/06/2020	09/12/2019	Study of lademirsen (SAR339375) in patients with Alport Syndrome	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients with Alport Syndrome - HERA	Congenital, hereditary and neonatal diseases MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Lademirsen Product Code: SAR339375 Other descriptive name: RG-012	Genzyme Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 2	France;United States;Spain;Australia;Germany;United Kingdom;China
2	NCT02855268 (ClinicalTrials.gov)	November 2, 2019	28/7/2016	Study of Lademirsen (SAR339375) in Patients With Alport Syndrome	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome	Alport's Syndrome	Drug: lademirsen (SAR339375);Drug: Placebo	Genzyme, a Sanofi Company	NULL	Active, not recruiting	18 Years	55 Years	All	43	Phase 2	United States;Australia;Canada;China;France;Germany;Spain;United Kingdom